PT-141 is unusual among the compounds covered on this site: it isn’t a research-only peptide hoping for a future indication. The molecule — properly called bremelanotide — already crossed the FDA finish line for a women’s condition, marketed as Vyleesi. But the approval is narrow and specific, and most of the confusion around “PT-141 for women” comes from glossing over how narrow it is. This page is about that boundary: who the approved indication actually covers, what the evidence shows in women, and how to tell whether you’re in the group it was designed for.
The one group it’s approved for
Bremelanotide was approved in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Every word in that phrase is doing work, and a provider deciding whether the drug fits you is essentially checking each one.
Premenopausal. The approval trials enrolled premenopausal women, so that’s the population where the safety and efficacy data live. It is explicitly not approved for postmenopausal women — more on why that matters below.
Acquired. This means you previously had a level of sexual desire that felt fine to you, and it declined. It’s the opposite of lifelong HSDD, where low desire has been present essentially since the beginning. The distinction isn’t academic: the drug was studied in women describing a change from their own baseline.
Generalized. Your low desire shows up broadly — across partners, situations, and types of stimulation — rather than being tied to one specific relationship or one set of circumstances. Situational low desire (for example, desire that’s fine in some contexts but absent in a particular relationship) points the workup in a different direction, often toward the relationship or context itself.
HSDD, causing distress. Low desire alone isn’t a disorder. The diagnosis requires that the low desire causes marked distress or interpersonal difficulty. Plenty of people have lower libido than they once did and feel perfectly fine about it — that’s not a condition to medicate.
Note: HSDD is partly a diagnosis of exclusion. By definition it is not attributable to a co-existing medical or psychiatric condition, to relationship problems, or to the effects of a medication or other drug. That “not due to” clause is the heart of a real evaluation.
Why the diagnosis is the whole game
Because HSDD is defined partly by what it isn’t, the honest version of this treatment starts with ruling things out — and that’s exactly the step gray-market shortcuts skip.
A careful provider will look at whether something else is driving the low desire. Depression and anxiety commonly blunt libido. So do thyroid and other hormonal issues. Pain with intercourse changes the picture entirely. And medications are a frequent, under-recognized culprit — SSRIs and other antidepressants in particular are well known for reducing desire, which is its own situation to address rather than a reason to layer on another drug. Relationship strain, life stress, and sleep deprivation all matter too.
If one of those explains the low desire, then by definition it isn’t HSDD, and bremelanotide isn’t the indicated answer — treating the underlying cause is. This is why “fill out a 30-second quiz and we’ll ship it” storefronts are a poor fit for this drug specifically: the entire value of the diagnosis is in the conversation a quiz can’t have.
A short screening tool called the Decreased Sexual Desire Screener (DSDS) is often used to start that discussion. It’s not a self-diagnosis instrument and it doesn’t replace an evaluation — it’s a structured way to raise something many women find awkward to bring up, and to help a provider decide whether a fuller HSDD workup makes sense.
What the evidence actually shows in women
This is where honesty matters most, because the marketing history of HSDD drugs has been louder than the data.
Bremelanotide was tested in two large, identical, six-month, randomized, placebo-controlled trials in roughly 1,200 premenopausal women with acquired, generalized HSDD (average age around 39). The results were genuinely positive on the desire-related measures: women on the drug showed statistically significant improvement in measured sexual desire and a significant reduction in distress compared with placebo.
But two caveats keep the picture honest. First, the trials did not show a significant increase in the number of satisfying sexual events — one of the outcomes you might intuitively expect a desire drug to move. The wins were on how women scored their desire and their distress, not on event counts. Second, tolerability was a real issue: about 18% of women discontinued because of side effects, compared with around 2% on placebo, with nausea the most common reason.
The fair summary is that bremelanotide produces a real but modest benefit for some women with HSDD — not a transformation, and not for everyone who tries it. If you want the effect-size and responder-rate detail, the libido page and the benefits page go deeper; the side-effect trade-offs live on the side effects page.
The premenopausal boundary — and what it means if you’re past it
The hard edge of this page is menopause. Bremelanotide is not approved for postmenopausal women, and the approval trials didn’t study them, so there is no approval-grade evidence in that group.
That’s not a technicality. Low desire around and after menopause often has different drivers — hormonal shifts, vaginal dryness and pain, sleep disruption, mood changes — and the workup and options differ accordingly. For postmenopausal women, the desire conversation frequently involves menopause-specific care, and some providers consider off-label approaches (including low-dose testosterone, which professional societies discuss for postmenopausal HSDD under specific conditions) that are entirely separate from bremelanotide.
If a postmenopausal woman is prescribed bremelanotide, it’s off-label, usually as a compounded product, and the evidence base simply isn’t there in the way it is for premenopausal women. That doesn’t make it categorically wrong, but it does change the risk-benefit math and the honesty of the conversation — and it’s a decision to make with a knowledgeable provider, not based on a website written for a different population. The legal mechanics of compounded versus approved bremelanotide are covered on the how to get PT-141 page.
Vyleesi vs Addyi: the within-women choice
If you are in the approved premenopausal group, bremelanotide isn’t the only FDA-approved option — and the two work very differently, which makes the choice as much about lifestyle as medicine.
Bremelanotide (Vyleesi) is an as-needed treatment: a single-use subcutaneous self-injection taken ahead of anticipated activity, working through brain melanocortin pathways tied to desire. You use it only when you want to, which suits women who’d rather not take something daily — at the cost of nausea being common and a transient blood-pressure effect that rules it out for women with uncontrolled hypertension or known cardiovascular disease.
Flibanserin (Addyi) is a daily oral pill that acts on serotonin pathways and is taken every day at bedtime. It builds up over weeks rather than working on demand, carries its own side effects (dizziness, sleepiness), and historically came with cautions around alcohol. Its appeal is that it’s a pill, not an injection, and that it’s available generically.
Neither is dramatically more effective than the other; they’re different trade-offs — on-demand injection versus everyday pill, different side-effect profiles, different rhythms of use. Both are approved for the same premenopausal HSDD population, so the “right” one is genuinely individual and a good thing to weigh with a provider.
The real-world availability picture
One more piece of honesty: being FDA-approved doesn’t mean a drug is easy to find or widely used.
Bremelanotide was once hyped as a “female Viagra,” and like the daily-pill option before it, commercial uptake has been modest — sales were a fraction of early forecasts. The product changed hands, moving from its original developer to Cosette Pharmaceuticals, which now markets it within a women’s-health portfolio. Industry surveys have suggested that a large majority of women who’d actually meet HSDD criteria don’t know it’s a recognized, treatable condition at all.
Practically, that means two things. It’s a real, approved prescription product — not a gray-market vial — which is a meaningful advantage on quality and oversight. But you may have to be the one who raises it, because awareness among both patients and some providers is low. Sexual-medicine and women’s-health specialists are the clinicians most likely to be comfortable evaluating HSDD and discussing the approved options. Pricing for the approved product is its own topic, covered on the cost page.
A note on pregnancy and safety
For women who can become pregnant, the approved labeling calls for effective contraception during treatment, and the drug isn’t recommended in pregnancy. As with the other PT-141 pages, this site doesn’t provide dosing instructions — bremelanotide is a prescription product whose use should be individualized by a licensed provider, and the deeper safety detail (the blood-pressure effect, nausea, pigmentation changes) is on the side effects page. The point of this page is upstream of dosing: figuring out whether you’re actually in the group the drug was approved to help.
Bottom line
PT-141 for women is a narrow, real thing. Bremelanotide has a legitimate FDA approval — but only for premenopausal women with acquired, generalized HSDD, a diagnosis defined as much by what it rules out as by what it includes. If that’s you, it’s one of two approved options worth discussing, with a modest but genuine evidence base. If you’re postmenopausal, if another cause better explains your low desire, or if you’re simply looking for a general libido boost, the approval doesn’t cover you, and the honest path runs through a proper evaluation first. That evaluation — not the injection — is the part that actually decides whether this drug belongs in your life.
This page is educational and current as of its last-updated date; regulatory and product details can change. It is not medical advice, and nothing here is a substitute for evaluation by a licensed provider.
Frequently asked questions
Is PT-141 FDA-approved for women?
Yes, but narrowly. As the brand Vyleesi, bremelanotide is approved for premenopausal women with acquired, generalized HSDD — low desire that causes real distress and isn't explained by another medical, psychiatric, relationship, or medication cause. It is not approved for postmenopausal women, for men, or as a general libido booster.
What does 'acquired, generalized' HSDD mean?
'Acquired' means you used to have a satisfying level of desire and it dropped off — as opposed to never having had much (lifelong). 'Generalized' means the low desire shows up across situations and partners, not only in one specific relationship or context. Both labels matter because that's the exact group studied for approval.
Can postmenopausal women use PT-141?
It's not FDA-approved for them, and the approval trials didn't include them, so there's no approval-grade evidence in that group. Some providers prescribe it off-label, often as a compounded product, but that's a different risk-benefit conversation — and menopause-related low desire is usually worked up differently.
How is PT-141 different from Addyi for women?
Both are FDA-approved for premenopausal HSDD but work differently. Bremelanotide (Vyleesi) is an as-needed self-injection taken ahead of anticipated activity; flibanserin (Addyi) is a daily pill that takes weeks to build up and has its own cautions. One is on-demand, the other is everyday — a lifestyle as much as a medical choice.
How well does it actually work in women?
The effect is real but modest. In two large trials, women on bremelanotide showed statistically significant gains in measured desire and reductions in distress versus placebo — but it did not significantly increase the number of satisfying sexual events, and about 18% stopped due to side effects, mostly nausea. It helps some women meaningfully, not most dramatically.
Do I need a diagnosis before getting it?
You should. A legitimate provider rules out other causes — depression, thyroid issues, medication effects like SSRIs, relationship factors — before settling on HSDD. A screening tool called the Decreased Sexual Desire Screener (DSDS) is often used to start that conversation. 'No evaluation, just inject' is a red flag.